A meaningful signal in diabetes
A placebo-controlled trial found lower HbA1c, a measure of average blood sugar, after three months in people with type 2 diabetes and abnormal blood lipids.
Not a finding in healthy adults. [1]
BERBERINE · HUMAN ORAL RESEARCH
Berberine.
A closer look at
metabolic health.
Clinical trials point to improvements in blood sugar and cholesterol in people with metabolic conditions. Weight and liver-fat findings are more mixed. Here is what the human evidence actually shows.
Explore the findingsIngredient and research-formulation evidence. None of the cited studies tested a finished Neurogan product.
01 / FINDINGS AT A GLANCE
More evidence for markers.
Less certainty about outcomes.
Berberine is a plant alkaloid. Human oral trials most often measure blood sugar and blood lipids, not whether people avoid heart attacks or other long-term complications.
Modest reductions in cholesterol
A review of placebo-controlled trials found lower LDL cholesterol and triglycerides. These are risk markers, not proof of fewer cardiovascular events.
Short trials, mostly in China and Hong Kong. [5]
Not a reliable fat-loss shortcut
A newer six-month trial found no significant benefit for visceral fat or liver fat in adults with obesity and fatty liver, but without diabetes.
337 participants in a blinded trial. [4]
02 / A CLOSER LOOK AT LIVER FAT
An encouraging trial.
A different result later.
Liver fat is fat stored inside the liver. Two studies tested different populations, doses and designs. Their results belong side by side, not in a single combined promise.
2015: change in liver fat after 16 weeks
Open-label, completer analysis. Adults had fatty liver plus impaired glucose regulation or diabetes. Both groups received diet and exercise advice. Of 62 randomized per arm, 53 and 55 completed. This is not evidence that healthy adults lose this amount of liver fat.
No clear advantage for visceral fat
Adjusted difference in relative change at six months: +1.38 percentage points for berberine versus placebo.
03 / THE HUMAN STUDIES
What was actually tested?
Study conditions matter. Positive blood tests, null results and tolerability all belong in the same picture.
Blood sugar and cholesterol in type 2 diabetes
What happened
HbA1c fell from 7.5% to 6.6% in the berberine group. Fasting glucose fell from 7.0 to 5.6 mmol/L; LDL cholesterol from 3.23 to 2.55 mmol/L. These endpoints differed significantly from placebo. [1]
What to keep in mind
The quoted before-and-after values are within the berberine group, not placebo-adjusted effects. Insulin sensitivity measured by a glucose clamp did not differ significantly between groups (p = 0.063).
Study details, safety & source access
Population and comparison: adults already had diabetes and abnormal lipids. This trial does not establish a preventive benefit in healthy users.
Safety: five berberine participants experienced mild to moderate constipation. Long-term outcomes were not established.
Access: primary abstract and trial registry reviewed. Arm-specific endpoint denominators and complete placebo values were not available in the retrieved abstract, so these results are not shown as a comparative chart.
Read the source [1]
An early comparison with metformin
What happened
The primary abstract reports berberine HbA1c changing from 9.5% to 7.5%. A separate 48-person add-on cohort reported a change from 8.1% to 7.3%.
What to keep in mind
The add-on cohort lacked a parallel control. Similar changes to metformin in a small pilot are not proof of drug equivalence, and do not justify stopping a prescription.
Study details, safety & source access
Formulation: berberine hydrochloride. The full-text extraction reports 15 berberine and 16 metformin participants in the final monotherapy analysis, and 43 in the add-on analysis. Existing treatments in the add-on cohort varied.
Safety: 20 of 58 analyzed berberine recipients across both cohorts had transient gastrointestinal symptoms (34.5%); dose reduction was sometimes needed. This combined safety denominator is not the monotherapy sample alone.
Access: primary abstract and a tool-extracted full-text summary reviewed. Raw full-text retrieval was blocked; no chart is based on an unverified primary table.
Read the source [2]
A liver-fat signal with lifestyle changes
What happened
Berberine plus lifestyle reduced liver fat more than lifestyle alone. Adjusted body-weight changes were −4.29 kg versus −1.99 kg. The liver-fat changes are visualized above.
What to keep in mind
There was no blinding or placebo. Fasting glucose, HbA1c and LDL changes did not differ significantly from lifestyle alone in Table 2. Weight and liver-fat changes are not interchangeable.
Study details, safety & source access
Methods: liver fat was measured with proton magnetic resonance spectroscopy. All groups were advised to reduce calories and exercise. Berberine was taken 30 minutes before meals. Completers: 55 berberine, 53 lifestyle and 47 pioglitazone.
Safety: digestive symptoms were the main berberine-related events; one berberine participant stopped treatment due to adverse events.
Access and numerical caution: primary full text and Table 2 reviewed. The abstract and main text disagree on relative liver-fat reduction (52.7% versus 57.2%). The chart uses the clearly tabulated adjusted absolute changes, not either conflicting percentage.
Read the source [3]
A larger trial did not confirm fat reduction
What happened
Neither visceral fat nor liver fat improved significantly versus placebo. LDL cholesterol was lower by an adjusted 7.72 mg/dL (95% CI −13.13 to −1.93).
What to keep in mind
LDL was a secondary outcome without multiplicity adjustment. Blood sugar, body composition and most other secondary outcomes were not significantly different. A favorable lipid result does not reverse the primary null findings.
Study details, safety & source access
Analysis: 169 assigned berberine and 168 placebo; intention-to-treat primary analyses adjusted for baseline outcome, with multiple imputation. The 97.5% intervals account for two primary endpoints. Secondary endpoints used complete cases.
Safety boundary: participants first completed a 30-day berberine run-in. People who could not tolerate it or adhered poorly were excluded before randomization. Similar adverse-event rates during the trial therefore do not describe all first-time users.
Access: primary full text, Table 2 and methods reviewed. Government research funding; study drugs supplied without charge by the manufacturer; no conflicts reported.
Read the source [4]
04 / THE BROADER PICTURE
What do pooled trials suggest?
Reviews can reveal a pattern, but do not remove limitations in the underlying studies.
Blood lipids: a modest average effect
The 2023 Blais review included 18 placebo-controlled studies, 1,788 participants and 4 to 24 weeks of treatment. The LDL analysis used 14 studies and 1,447 participants: mean difference −0.46 mmol/L (95% CI −0.62 to −0.30). Triglycerides also decreased.
Most studies were in mainland China or Hong Kong. Gastrointestinal events tended to be more common with berberine. These are lipid outcomes, not demonstrated reductions in heart attacks. [5]
Metabolic markers: not every endpoint improves
A 2025 placebo-controlled trial review found favorable average changes in fasting glucose, triglycerides and waist circumference, but no significant pooled effect on HDL cholesterol or blood pressure.
It evaluated components of metabolic syndrome, not reversal of the whole syndrome. Different populations and trial quality limit a one-size-fits-all expectation. The 2026 null trial above also postdates these reviews. [6]
05 / FROM RESEARCH TO PRODUCT
The label is not a clinical trial.
None of the studies on this page tested Neurogan Health Berberine Capsules.
Neurogan Health Berberine Capsules
The live Supplement Facts image lists 1,000 mg berberine per two-capsule serving, with 45 servings in a 90-capsule bottle. Other ingredient: vegetable cellulose capsule.
The product record directs two capsules daily, ideally 20 to 30 minutes before a meal. This is label information, not a recommendation derived from these trials.
| Comparison | Research exposure | What the label establishes |
|---|---|---|
| Daily amount | 1,000 mg/day in Zhang and Lei; 1,500 mg/day in Yin and Yan. | The listed daily amount overlaps some trials numerically. It does not prove equivalence. |
| Chemical form | Several trials explicitly used berberine hydrochloride. | The displayed label says berberine; it does not specify salt form or an independently assayed active-base amount. |
| Schedule | Divided doses were common; meals and schedules varied. | Two capsules once daily before a meal are not the same protocol as two separated daily doses. |
| DHB | Dihydroberberine is a related but distinct administered ingredient. | Berberine outcomes cannot be transferred to DHB. Read the DHB evidence review. |
06 / SAFETY & PRACTICAL LIMITS
Check interactions before use.
A supplement can affect biology and still require the same care you would give other active substances.
Digestive effects are real
Nausea, abdominal pain, bloating, constipation and diarrhea have been reported. Tolerability varies by dose, person and other treatment. A short trial without serious events cannot establish safety over years.
Medicines need a review
Ask a clinician or pharmacist before combining berberine with medicines, particularly glucose-lowering treatment or drugs with narrow dosing margins. NCCIH highlights an interaction with cyclosporine, used after organ transplantation.
Pregnancy, nursing and infants
NCCIH advises against berberine during pregnancy or breastfeeding and for infants. Berberine exposure can cause or worsen bilirubin-related harm in newborns.
Use medical monitoring, not guesswork
If you have diabetes, liver disease or high cholesterol, discuss treatment and monitoring with your clinician. Do not stop or replace prescribed care based on a supplement trial. [7]
THE TAKEAWAY
Promising for blood markers.
Not a metabolic cure-all.
Berberine has human evidence for glucose and lipid changes in selected populations. Fat-loss results are less consistent, and the finished product, dose schedule and long-term outcomes still matter.
Read the original research ↓08 / SOURCES & FURTHER READING
Follow each finding to its source.
A focused human oral evidence review, not a systematic review. Literature and live product records checked September 10, 2026. Reviews overlap with individual trials and are not counted as new participants.
- PRIMARY ABSTRACT
Zhang et al. Treatment of type 2 diabetes and dyslipidemia with berberine
JCEM, 2008. PMID 18397984. DOI 10.1210/jc.2007-2404. Primary abstract reviewed; no comparative chart inferred from missing placebo values.
Read the source ↗ - PRIMARY ABSTRACT + FULL-TEXT EXTRACTION
Yin et al. Efficacy of berberine in patients with type 2 diabetes mellitus
Metabolism, 2008. PMID 18442638. DOI 10.1016/j.metabol.2008.01.013. Two separate cohorts; not proof of equivalence to metformin.
Read the source ↗ - PRIMARY FULL TEXT
Yan et al. Efficacy of berberine in patients with non-alcoholic fatty liver disease
PLOS ONE, 2015. PMID 26252777. DOI 10.1371/journal.pone.0134172. Chart: Table 2 adjusted HFC changes and completer denominators.
Read the source ↗ - PRIMARY FULL TEXT
Lei et al. Berberine and adiposity in diabetes-free individuals with obesity and MASLD
JAMA Network Open, 2026. PMID 41543854. DOI 10.1001/jamanetworkopen.2025.54152. Chart: Table 2, visceral-fat treatment difference; methods explain run-in and imputation.
Read the source ↗ - SYSTEMATIC REVIEW · ABSTRACT
Blais et al. Berberine for dyslipidemia in adults
Drugs, 2023. PMID 36941490. DOI 10.1007/s40265-023-01841-4. 18 placebo-controlled trials; outcome-specific denominators vary.
Read the source ↗ - SYSTEMATIC REVIEW · FULL TEXT
Efficacy and safety of berberine on components of metabolic syndrome
2025. PMID 40740996. Placebo-controlled RCT review, including both favorable and null metabolic-marker findings.
Read the source ↗ - AUTHORITATIVE SAFETY GUIDANCE
NCCIH: Berberine and weight loss
U.S. National Center for Complementary and Integrative Health. Evidence limits, gastrointestinal effects, interactions and pregnancy/infant cautions.
Read the source ↗